

# BFPT-6864 - Rheumatoid Arthritis

## Overview / Indication:

**B**aroFold is developing a novel construct for the treatment of Rheumatoid Arthritis. Rheumatoid Arthritis is a chronic auto-immune disease, characterized by inflammation of the joints. RA patients usually progress after first line treatment with disease-modifying antirheumatic drugs (DMARDs) leading to permanent joint damage, chronic pain, and disability. Current treatment methods focus on relieving pain, reducing inflammation, and stopping or slowing joint damage.

**B**FPT-6864 is being developed as a more effective drug for managing moderate to severe RA patients that are experiencing an inadequate response to current therapies.


Attribute	TARGET PROFILE			
	Drug	BFPT-6864 *	Orencia®	Rituxan®
Delivery		Subcutaneous	Intravenous Infusion	Intravenous Infusion
Mechanism		Proprietary	CTLA4-IgG	Anti CD20 Antibody
Patients		Anti-TNF Failures Anti-TNF Naive	Anti-TNF Failures Anti-TNF Naive	Anti-TNF Failures
Safety				Black Box Warning
Efficacy		High	Moderate	Moderate

\* Drug candidate not approved by FDA      Rituxan® is a registered trademark of Genentech  
Orencia® is a registered trademark of Bristol Myers-Squibb Company

## Market Opportunity - Biologics\*

- Estimates suggest that 20-40% of RA patients will fail anti-TNF therapy at some point
- Biologics are the fastest growing therapeutic area for treating RA patients that no longer respond to DMARDs
- Significant demand for faster acting, more effective therapies in hard to treat populations
- Delivery and side effects remain important considerations for patients and physicians

### WW Market Estimates - Patients



## Summary

**B**aroFold believes that it can provide a superior solution for those patients who fail TNF inhibitor therapy or are no longer experiencing an adequate response as determined by their healthcare provider. BaroFold's goal is to develop a drug for RA treatment that is more efficacious, while providing a faster onset of action, and a more convenient delivery profile than current therapies.

\* References available

1745 38th Street • Boulder, CO 80301  
p: 303-926-0337 • f: 303-926-4292 • www.barofold.com

#0003-07-K-04

**BAROFOLD**  
IMPROVING PROTEIN THERAPEUTICS,  
IMPROVING PEOPLE'S LIVES